Le Lézard
Classified in: Health, Business
Subjects: SVY, POL

Prior authorization obstacles unnecessarily delay patient access to cancer treatments, physician survey finds


ARLINGTON, Va., April 25, 2019 /PRNewswire/ -- Restrictive prior authorization practices cause unnecessary delays and interference in care decisions for cancer patients, according to a new survey of nearly 700 radiation oncologists ? physicians who treat cancer patients using radiation ? released today by the American Society for Radiation Oncology (ASTRO). Leaders from ASTRO, the American Medical Association (AMA) and the National Coalition for Cancer Survivorship also discussed the impact on patients in an online presscast.

American Society for Radiation Oncology (ASTRO) www.astro.org (PRNewsfoto/ASTRO)

In the survey, nearly all radiation oncologists (93%) said that their patients are delayed from life-saving treatments, and a third (31%) said the average delay lasts longer than five days ? a full week of standard radiation treatments. These delays cause added stress and anxiety to patients already concerned about their health, and they are cause for alarm given research linking each week of delay in starting cancer therapy with a 1.2% to 3.2% increased risk of death.

In addition to prevalent treatment delays, the ASTRO physician survey illuminates other ways prior authorization negatively impacts patient outcomes and takes physicians away from caring for their patients:

Added Patient Stress

Unnecessary Delay Tactics

Wasting Physician Time

Disproportionate Impact on Patients at Community-Based Clinics

"This survey makes clear that restrictive prior authorization practices can cause unnecessary, stressful and potentially life-threatening delays for cancer patients," said Paul Harari, MD, FASTRO, Chair of the ASTRO Board of Directors and professor and Chairman of human oncology at the University of Wisconsin-Madison. "While the system may have been designed as a path to streamline and strengthen health care, it is in fact frequently harmful to patients receiving radiation therapy. In its current form, prior authorization causes immense anxiety and wastes precious time for cancer patients."

"Radiation oncology and cancer patients have been particularly hard hit by prior authorization's unnecessary burden and interference in care decisions," said Vivek Kavadi, MD, Vice Chair of ASTRO's Payer Relations Subcommittee and a radiation oncologist at Texas Oncology. "Radiation oncologists increasingly are restricted from exercising our clinical judgment in what is in the best interest of the patient, yet we are held accountable for the outcomes of treatments where decisions have been taken out of our hands."

In the 2018 annual ASTRO member survey, radiation oncologists named prior authorization as the greatest challenge facing the field. The burden was especially prominent among private practitioners in community-based settings, where the majority of cancer patients receive care.

The findings from ASTRO's new physician survey align with recent reports from the American Medical Association (AMA), American Cancer Society Cancer Action Network (ACS CAN) and others, demonstrating the pervasiveness of prior authorization obstacles throughout the American health care system.

ASTRO recently signed onto a letter with the AMA and other medical societies calling for CMS to require Medicare Advantage plans to align their prior authorization requirements with a Consensus Statement on Improving the Prior Authorization Process authored jointly by leading provider and payer organizations.

Survey Methodology

An online survey was sent by email to all 3,882 U.S. based, practicing radiation oncologists in ASTRO's member database, and 620 physicians completed the survey online. Invitations were sent in December 2018, with one email reminder in January 2019, and the survey closed in February 2019. ASTRO staff also administered paper surveys at the ASTRO Annual Meeting in October 2018 and collected 53 responses. Findings reflect the combined total of 673 radiation oncologist responses. For more information about respondent demographics, view the executive summary.

ABOUT ASTRO

The American Society for Radiation Oncology (ASTRO) is the world's largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology ? Biology ? Physics, Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, RT Answers; and created the nonprofit foundation Radiation Oncology Institute. To learn more about ASTRO, visit our website, sign up to receive our news and follow us on our blog, Facebook, Twitter and LinkedIn.

Liz Gardner, 703-286-1600, [email protected]
Jeff White, 703-839-7392, [email protected]

SOURCE American Society for Radiation Oncology


These press releases may also interest you

at 09:00
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...

at 09:00
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...

at 09:00
Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a...

at 09:00
Arbele, a clinical-stage biotechnology company focused...

at 08:53
Alera Health, a leader in population health management integrating behavioral healthcare, is proud to announce its recognition as one of the Great Employers to Work for in North Carolina by Best Companies Group. The 2024 Great Employers to Work for...



News published on and distributed by: